Assessment of the involvement of the macrophage migration inhibitory factor–glucocorticoid regulatory dyad in the expression of matrix metalloproteinase‐2 during periodontitis
Abstract:Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine and counter-regulator of endogenous glucocorticoids. It is implicated in acute and chronic inflammatory diseases. This study investigated the role of the MIF-glucocorticoid (GC) regulatory dyad in MMP2 expression and release during periodontitis in vivo and in vitro. In a MIF knockout (KO) mouse model of ligature-induced periodontitis, gingival tissues and blood were collected and analyzed for levels of IL6, MIF, MMP2 and corticosterone… Show more
“…1). These data indicate that MIF mRNA expression appeared to be upregulated in the periradicular lesion induced in mice, corresponding to our previously published report, demonstrating that expression of MIF mRNA as well as its protein level are elevated in the experimental periodontitis induced in mice by ligature attachment (21).…”
Section: Expression Of Mif Mrna In a Mouse Periradicular Lesionsupporting
confidence: 91%
“…Although a plethora of studies has demonstrated the pathogenic roles of MIF, a variety of medical complications, such as heart failure, type two diabetes, and rheumatoid arthritis in the past decades (48)(49)(50)(51), and MIF's role in the bone pathophysiology remains controversial. Our group and others reported that MIF promotes osteoclastogenesis in vitro and upregulates the pathogenic bone resorption in various mouse models of osteolytic lesions (16,19,21). However, one research group reported that MIF deficiency inhibits both osteoclast and osteoblast activities without changing the numbers of osteoblasts or osteoclasts and reduces the bone mass in the context of homeostatic bone remodeling (42,52).…”
Section: Discussionmentioning
confidence: 86%
“…We recently found that locally produced MIF is engaged in chemoattraction of osteoclast precursors (OCPs) to the inflammatory bone resorption site in the osteolytic lesions induced by bone-cement wear debris in a CXCR4-dependent manner, whereas SDF-1 (CXCL12), the other chemokine that binds to CXCR4, facilitates the chemotaxis of OCPs in the healthy bone-remodeling site (16). Pathogenic engagement of MIF is implicated in inflammatory bone destructive diseases, such as rheumatoid arthritis (19) and marginal periodontitis (20,21). Nonetheless, although Liu and Peng (22) reported the coexpression of MIF and RANKL in the periradicular lesion induced in rats, the functional role of MIF in alveolar bone resorption in the periapical periodontitis has not yet been addressed.…”
Locally produced osteoclastogenic factor RANKL plays a critical role in the development of bone resorption in periradicular periodontitis. However, because RANKL is also required for healthy bone remodeling, it is plausible that a costimulatory molecule that upregulates RANKL production in inflammatory periradicular periodontitis may be involved in the pathogenic bone loss processes. We hypothesized that macrophage migration inhibitory factor (MIF) would play a role in upregulating the RANKL-mediated osteoclastogenesis in the periradicular lesion. In response to pulp exposure, the bone loss and level of MIF mRNA increased in the periradicular periodontitis, which peaked at 14 d, in conjunction with the upregulated expressions of mRNAs for RANKL, proinflammatory cytokines (TNF-a, IL-6, and IL-1b), chemokines (MCP-1 and SDF-1), and MIF's cognate receptors CXCR4 and CD74. Furthermore, expressions of those mRNAs were found significantly higher in wild-type mice compared with that of MIF 2/2 mice. In contrast, bacterial LPS elicited the production of MIF from ligament fibroblasts in vitro, which, in turn, enhanced their productions of RANKL and TNF-a. rMIF significantly upregulated the number of TRAP + osteoclasts in vitro. Finally, periapical bone loss induced in wild-type mice were significantly diminished in MIF 2/2 mice. Altogether, the current study demonstrated that MIF appeared to function as a key costimulatory molecule to upregulate RANKL-mediated osteoclastogenesis, leading to the pathogenically augmented bone resorption in periradicular lesions. These data also suggest that the approach to neutralize MIF activity may lead to the development of a therapeutic regimen for the prevention of pathogenic bone loss in periradicular periodontitis.
“…1). These data indicate that MIF mRNA expression appeared to be upregulated in the periradicular lesion induced in mice, corresponding to our previously published report, demonstrating that expression of MIF mRNA as well as its protein level are elevated in the experimental periodontitis induced in mice by ligature attachment (21).…”
Section: Expression Of Mif Mrna In a Mouse Periradicular Lesionsupporting
confidence: 91%
“…Although a plethora of studies has demonstrated the pathogenic roles of MIF, a variety of medical complications, such as heart failure, type two diabetes, and rheumatoid arthritis in the past decades (48)(49)(50)(51), and MIF's role in the bone pathophysiology remains controversial. Our group and others reported that MIF promotes osteoclastogenesis in vitro and upregulates the pathogenic bone resorption in various mouse models of osteolytic lesions (16,19,21). However, one research group reported that MIF deficiency inhibits both osteoclast and osteoblast activities without changing the numbers of osteoblasts or osteoclasts and reduces the bone mass in the context of homeostatic bone remodeling (42,52).…”
Section: Discussionmentioning
confidence: 86%
“…We recently found that locally produced MIF is engaged in chemoattraction of osteoclast precursors (OCPs) to the inflammatory bone resorption site in the osteolytic lesions induced by bone-cement wear debris in a CXCR4-dependent manner, whereas SDF-1 (CXCL12), the other chemokine that binds to CXCR4, facilitates the chemotaxis of OCPs in the healthy bone-remodeling site (16). Pathogenic engagement of MIF is implicated in inflammatory bone destructive diseases, such as rheumatoid arthritis (19) and marginal periodontitis (20,21). Nonetheless, although Liu and Peng (22) reported the coexpression of MIF and RANKL in the periradicular lesion induced in rats, the functional role of MIF in alveolar bone resorption in the periapical periodontitis has not yet been addressed.…”
Locally produced osteoclastogenic factor RANKL plays a critical role in the development of bone resorption in periradicular periodontitis. However, because RANKL is also required for healthy bone remodeling, it is plausible that a costimulatory molecule that upregulates RANKL production in inflammatory periradicular periodontitis may be involved in the pathogenic bone loss processes. We hypothesized that macrophage migration inhibitory factor (MIF) would play a role in upregulating the RANKL-mediated osteoclastogenesis in the periradicular lesion. In response to pulp exposure, the bone loss and level of MIF mRNA increased in the periradicular periodontitis, which peaked at 14 d, in conjunction with the upregulated expressions of mRNAs for RANKL, proinflammatory cytokines (TNF-a, IL-6, and IL-1b), chemokines (MCP-1 and SDF-1), and MIF's cognate receptors CXCR4 and CD74. Furthermore, expressions of those mRNAs were found significantly higher in wild-type mice compared with that of MIF 2/2 mice. In contrast, bacterial LPS elicited the production of MIF from ligament fibroblasts in vitro, which, in turn, enhanced their productions of RANKL and TNF-a. rMIF significantly upregulated the number of TRAP + osteoclasts in vitro. Finally, periapical bone loss induced in wild-type mice were significantly diminished in MIF 2/2 mice. Altogether, the current study demonstrated that MIF appeared to function as a key costimulatory molecule to upregulate RANKL-mediated osteoclastogenesis, leading to the pathogenically augmented bone resorption in periradicular lesions. These data also suggest that the approach to neutralize MIF activity may lead to the development of a therapeutic regimen for the prevention of pathogenic bone loss in periradicular periodontitis.
“…Excessive inflammation of the periodontal tissues (periodontitis) is the hallmark feature of PD. In PD, bacteria in the oral biofilm interfere with the body's defense mechanisms, activating the immune system which in turn results in inflammation and the immune response [17,18]. The levels of C-reactive protein, prostaglandin E 2 interleukin-1beta, and tumor necrosis factor alpha increase in PD [19].…”
Introduction: It is well established that periodontal disease (PD) and diabetes mellitus (DM) can have a detrimental effect on each other's disease course, and that cigarette smoking exacerbates both conditions. However, literature on the periodontal status of smokers with DM is scarce, and the studies conducted to date did not use healthy controls or non-smokers with DM as controls. Consequently, the individual effects of smoking and DM on PD are difficult to untangle and estimate. Methods: A total of 128 participants were recruited to this study and their data analyzed. They were assigned to four groups: smoking
“…Some studies have identified MIF overexpression in GCF from subjects with gingivitis [23], in gingival tissue from subjects with CP, in serum and tissue of mice with induced periodontitis [15, 30]. In addition, it has been described that MIF gene polymorphism ( MIF -173 G/C) increased the risk of CP [31].…”
Chronic periodontitis (CP) is an infection that affects the teeth supporting structure. Macrophage migration inhibitory factor (MIF) is an important effector cytokine of the innate immune system. Due to its functional characteristics, MIF may be involved in the immunopathology of CP. The aim of the present study was to evaluate MIF levels in gingival crevicular fluid (GCF), saliva, and serum of CP patients. A cross-sectional study was conducted on 60 subjects divided into two groups: subjects with CP (n= 30) and periodontally healthy subjects without CP (n=30). MIF was quantified in GCF, saliva, and serum of all participants by enzyme-linked immunosorbent assay. MIF concentrations were higher in GCF, saliva, and serum in the group with CP compared with the group without CP and a higher MIF concentration was observed in GCF (p=0.001) and saliva (p=0.009) in the group with CP. MIF intragroup comparisons between fluids demonstrated significant high levels of MIF in saliva compared with GCF and serum in both study groups (p<0.05). A positive correlation was found between clinical signs and MIF concentration in GCF (p<0.05). There is an association between the MIF and the clinical signs of the disease. Therefore, MIF could have an important role in the pathology and progression of CP.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.